The potential applications of artificial intelligence in drug discovery and development

Author:

Farghali H,Kutinová Canová N1,Arora M

Affiliation:

1. Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic. ncano@lf1.cuni.cz

Abstract

Development of a new dug is a very lengthy and highly expensive process since only preclinical, pharmacokinetic, pharmacodynamic and toxicological studies include a multiple of in silico, in vitro, in vivo experimentations that traditionally last several years. In the present review, we briefly report some examples that demonstrate the power of the computer-assisted drug discovery process with some examples that are published and revealing the successful applications of artificial intelligence (AI) technology on this vivid area. Besides, we address the situation of drug repositioning (repurposing) in clinical applications. Yet few success stories in this regard that provide us with a clear evidence that AI will reveal its great potential in accelerating effective new drug finding. AI accelerates drug repurposing and AI approaches are altogether necessary and inevitable tools in new medicine development. In spite of the fact that AI in drug development is still in its infancy, the advancements in AI and machine-learning (ML) algorithms have an unprecedented potential. The AI/ML solutions driven by pharmaceutical scientists, computer scientists, statisticians, physicians and others are increasingly working together in the processes of drug development and are adopting AI-based technologies for the rapid discovery of medicines. AI approaches, coupled with big data, are expected to substantially improve the effectiveness of drug repurposing and finding new drugs for various complex human diseases.

Publisher

Institute of Physiology of the Czech Academy of Sciences

Subject

General Medicine,Physiology

Reference22 articles.

1. ARSHADI AK, SALEM M, COLLINS J, YUAN JS, CHAKRABARTI, D DEEPMALARIA: Artificial Intelligence Driven Discovery of Potent Antiplasmodials. Front Pharmacol 10: e1526, 2020. https://doi.org/10.3389/fphar.2019.01526

2. ATTIA YM, EWIDA H, AHMED MS: Chapter 8 - Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma. In: Drug Repurposing in Cancer Therapy. KWK TO, WCS CHO (eds), Academic Press, Elsevier Inc. All, 2020, pp 213-229. https://doi.org/10.1016/B978-0-12-819668-7.00008-7

3. BAEK M, DIMAIO F, ANISHCHENKO I, DAUPARAS J, OVCHINNIKOV S, LEE GR, WANG J, CONG Q, KINCH LN, SCHAEFFER RD, MILLÁN C, PARK H, ADAMS C, GLASSMAN CR, DEGIOVANNI A, PEREIRA JH, RODRIGUES AV, VAN DIJK AA, EBRECHT AC, OPPERMAN DJ, SAGMEISTER T, BUHLHELLER C, PAVKOV-KELLER T, RATHINASWAMY MK, DALWADI U, YIP CK, BURKE JE, GARCIA KC, GRISHIN NV, ADAMS PD, READ RJ, BAKER D: Accurate prediction of protein structures and interactions using a three-track neural network. Science 373: 871-876, 2021. https://doi.org/10.1126/science.abj8754

4. BALFOUR H: DSP-1181: drug created using AI enters clinical trials. European Pharmaceutical Review – News on 4 February DSP-1181, 2020: drug created using AI enters clinical trials (europeanpharmaceuticalreview.com)

5. BARNETTE DA, DAVIS MA, DANG NL, PIDUGU AS, HUGHES T, SWAMIDASS SJ, BOYSEN G, MILLER GP: Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches. Biochem Pharmacol 156: 10-21, 2018. https://doi.org/10.1016/j.bcp.2018.07.043

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3